目的 探讨平消胶囊联合注射用卡瑞利珠单抗治疗非小细胞肺癌的临床疗效。方法 选取空军第九八六医院在2021年3月—2024年2月收治的100例非小细胞肺癌患者，按随机数字表法将所有患者分为对照组和治疗组，各包括50例。对照组患者静脉滴注注射用卡瑞利珠单抗，200 mg/次，每3周1次。治疗组患者于对照组基础上口服平消胶囊，4粒/次，3次/d。3周为1个周期，两组持续治疗4个周期。比较两组临床疗效、健康状态、生活质量、淋巴细胞和血清指标。结果 治疗组、对照组的疾病控制率分别为92.00%、76.00%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组KPS评分高于治疗前（P＜0.05），与对照组相比，治疗组的KPS评分更高（P＜0.05）。治疗后，两组功能评分、总健康评分、症状评分均低于治疗前（P＜0.05）；治疗组的QLQ-C30各项评分低于对照组（P＜0.05）。治疗后，两组的CD4⁺、CD4⁺/CD8⁺高于治疗前（P＜0.05）；治疗组的CD4⁺、CD4⁺/CD8⁺高于对照组（P＜0.05）。治疗后，两组的血清神经元特异性烯醇化酶（NSE）、细胞角蛋白19片段抗原（CYFRA21-1）、肿瘤特异性生长因子（TSGF）水平均显著降低（P＜0.05），且治疗组血清肿瘤标志物水平较对照组更低（P＜0.05）。结论 平消胶囊联合注射用卡瑞利珠单抗治疗非小细胞肺癌可改善患者健康状态和生活质量，提高免疫功能，降低肿瘤标志物水平。

Objective To investigate the clinical effect of Pingxiao Capsules combined with Carrilizumab for injection in treatment of non-small cell lung cancer. Methods A total of 100 patients with non-small cell lung cancer admitted to the 986th Air Force Hospital from March 2021 to February 2024 were selected and divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were iv Carrilizumab for injection, 200 mg/time, once every 3 weeks. Patients in the treatment group were po Pingxiao Capsules on the basis of the control group, 4 capsules/time, 3 times daily. Three weeks was one course, and patients in both groups were treated continuously for four courses. The clinical efficacy, health status, quality of life, lymphocyte, and serum indexes were compared between two groups. Results The disease control rate of treatment group and control group was 92.00% and 76.00%, respectively, and the difference was statistically significant between groups (P < 0.05). After treatment, KPS scores in both groups were higher than theses before treatment (P < 0.05), and KPS scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the functional scores, total health scores, and symptom scores of both groups were lower than theses before treatment (P < 0.05). The scores of QLQ-C30 in the treatment group were lower than those in the control group (P < 0.05). After treatment, CD4⁺ and CD4⁺/CD8⁺ in both groups were higher than these before treatment (P < 0.05). CD4⁺ and CD4⁺/CD8⁺ in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of NSE, CYFRA21-1, and TSGF in both groups were significantly decreased (P < 0.05), and the serum tumor marker levels in the treatment group were lower than those in the control group (P < 0.05). Conclusion Pingxiao Capsules combined with Carrilizumab for injection can improve the health status and quality of life of patients with non-small cell lung cancer, improve immune function and reduce the level of tumor markers.

R979.1

空军军医大学临床研究项目（2023 LC2331）